Biological dose escalation through stereotactic ablative radiotherapy (SABR) holds promise of improved patient convenience, system capacity and tumor control with decreased cost and side effects. The objectives are to report the toxicities, biochemical and pathologic outcomes of this prospective study.
Bibliographical noteCopyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Loblaw, A., Cheung, P., D'Alimonte, L., Deabreu, A., Mamedov, A., Zhang, L., Tang, C., Quon, H., Jain, S., Pang, G., & Nam, R. (2013). Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes. Radiotherapy and Oncology, 107(2), 153-158. https://doi.org/10.1016/j.radonc.2013.03.022